Clinical-stage drug discovery and development company developing AST-004 and other neuroprotective therapies that harness astrocytes to protect brain tissue and support recovery after traumatic brain injury, concussion, acute ischemic stroke, and potentially neurodegenerative and other neurological disorders
Clinical-stage drug discovery and development company developing AST-004 and other neuroprotective therapies that harness astrocytes to protect brain tissue and support recovery after traumatic brain injury, concussion, acute ischemic stroke, and potentially neurodegenerative and other neurological disorders. AST-004 is a small-molecule adenosine A1/A3 receptor agonist; it has completed Phase 1 studies and is advancing through Phase 2 clinical development.